About the Company
Regulus Therapeutics Inc. or Regulus (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RGLS News
Greenville-based Zylo Therapeutics creates spinoff company
Greenville-based Zylö Therapeutics has created a spinoff company to market its trademarked Z-pod topical delivery platform in ...
Global Antisense and RNAi Therapeutics Report 2024: A USD 34.7 Billion Predicted Market by 2034, with CAGR of 18% During 2024-2034
Treatment for particular genetic defects can be personalized with antisense and RNA interference therapies. The ability to ...
NASA back in communication with Voyager I, now 15 billion miles away | The Sky Guy
A fter five months NASA’s Voyager 1 spacecraft is once again returning usable data to Earth. Voyager 1 stopped sending usable ...
Loading the latest forecasts...